Questions & Answers: Is Strattera dangerous?

Q. What is the significance of the new warnings about suicide risk with Strattera?

A. In September 2005, the FDA directed the manufacturer of atomoxetine (Strattera), a new treatment marketed in 2002 for attention deficit hyperactivity disorder (ADHD), to warn consumers that suicidal thinking may increase in a small number of children taking the drug. Parents will be advised to alert the treating health care professional immediately about a child's worsening mood or thoughts of suicide.

Similar warnings were issued earlier in 2005 for all antidepressant medications. The addition of atomoxetine is not surprising, since it resembles some antidepressants in its mechanism of action.

To continue reading this article, you must login.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »